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While limited observational evidence suggests that cancer survivors have a decreased risk of developing 
Alzheimer’s disease (AD), and vice versa, it is not clear whether this relationship is causal. Using a 
Mendelian randomization approach that provides evidence of causality, we found that genetically 
predicted lung cancer (OR 0.91, 95% CI 0.84–0.99, p = 0.019), leukemia (OR 0.98, 95% CI 0.96–0.995, 
p = 0.012), and breast cancer (OR 0.94, 95% CI 0.89–0.99, p = 0.028) were associated with 9.0%, 2.4%, 
and 5.9% lower odds of AD, respectively, per 1-unit higher log odds of cancer. When genetic predictors 
of all cancers were pooled, cancer was associated with 2.5% lower odds of AD (OR 0.98, 95% CI 0.96–
0.988, p = 0.00027) per 1-unit higher log odds of cancer. Finally, genetically predicted smoking-related 
cancers showed a more robust inverse association with AD than non-smoking related cancers (OR 0.95, 
95% CI 0.92–0.98, p = 0.0026, vs. OR 0.98, 95% CI 0.97–0.995, p = 0.0091).
Individuals with a history of cancer are less likely to develop Alzheimer’s disease (AD), and vice versa1–3. This epi-
demiological observation remains unexplained, although biologically plausible mechanisms have been proposed: 
while cancer is a disorder of excessive cell proliferation, neurodegeneration is one of premature cell death. The 
dysregulation of mutual genes, proteins, and pathways in both conditions has been demonstrated4. For instance, 
the expression of the tumor suppressor TP53, which is notably downregulated in the majority of cancers, is upreg-
ulated in AD. The opposite is true for PIN1, an enzyme promoter of cell proliferation4.
The magnitude of the association between AD and cancer varies greatly across studies. In one 
population-based prospective study, those with prevalent cancer had a 69% lower risk of developing AD after 
controlling for numerous factors5. Another found that those with a history of cancer had just a 13% lower risk 
of subsequent AD6. Others report a trend without reaching statistical significance7,8, or no association between 
a history of cancer and the risk of AD9. In light of these findings, it is important to consider the potential for bias 
and confounding behind these associations. The reduced risk of AD in those diagnosed with cancer may be due 
to higher mortality rates among cancer patients and survivors, especially for cancers with poor survival rates, 
such as pancreatic cancer10. Many studies are limited by small sample sizes7,11,12, short follow-up periods7,9,12,13, or 
gender bias9. Other issues include appropriate diagnoses and changing guidelines, the potential negative effects 
of chemotherapy on cognition, and behavioral and sociodemographic variables related to both AD and cancer.
A fundamental question remains: is cancer causally related to AD, or is the observed epidemiological rela-
tionship between the two disorders an artifact of study design, confounding and biases? This study uses a genetic 
approach to determine the nature of the association between cancer and AD. The alleles of cancer–associated 
genetic variants are randomly allocated and are not typically associated with the range of social, behavioral, and 
physiological factors that can influence the observed relationship between cancer and Alzheimer’s disease. Thus, 
the method of Mendelian randomization, in which genetic variants are used as a proxy for cancer, represents a 
valid alternative to assess the causal relationship between cancer and Alzheimer’s disease by avoiding issues of 
confounding or reverse-causality14.
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Prior literature was used to identify genetic variants that influence susceptibility to cancer. Data from the 
International Genomics of Alzheimer’s Project (IGAP) were then utilized to examine the theoretically uncon-
founded association between these cancer-predicting genes and the risk of AD. This approach addresses two 
major limitations of previous observational studies: the potential for reverse-causation and the confounding 
effects of environmental risks15. We predicted that genes that have been associated with increased risk of cancer 
are associated with reduced risk of AD, in independent cohorts.
Methods
Overview. The summary-data-based Mendelian randomization method consists of three key steps in data 
preparation and cleaning: (1) the identification of single nucleotide polymorphisms (SNPs) associated with the 
exposure (in this case, cancer), (2) the determination of SNP-effects on the outcome (in this case, AD), and (3) 
Mendelian randomization analysis to examine the causal effect of the exposure on the outcome.
Defining instrumental variables for cancer. Identifying relevant cancer types: systematic literature 
review. To identify cancer types with epidemiological evidence of association with AD, PubMed (NCBI) and 
Web of Science (EBSCO) were systematically searched using a combination of medical subject headings [MeSH] 
and keyword strings (Fig. 1A). Identified papers were then examined against a predetermined set of inclusion 
criteria to determine eligibility (Fig. 1B).
Identifying cancer-associated genetic variants: review of GWAS literature. After identifying cancers with prior 
evidence of association with AD, the Genome-Wide Association Studies (GWAS) Catalog was used to iden-
tify genetic variants associated with each cancer type (04/06/18)16. The GWAS Catalog (https://www.ebi.ac.uk/
gwas/docs/about) was launched in 2008 by the National Human Genome Research Institute to systematically 
catalogue and summarize SNP-trait associations from all published GWAS16. The repository is updated on a 
weekly basis by an experienced team of molecular biologists with support from The European Bioinformatics 
Figure 1. Literature review search strategy.
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Institute (EMBL-EBI) and input from an independent Scientific Advisory Board. This tool was used to identify 
published GWAS reporting cancer susceptibility SNPs. Each paper was then manually examined for content and 
data retrieval.
Only studies conducted or replicated in individuals of European decent were considered in order to ena-
ble meaningful comparison with the population used in IGAP for Mendelian randomization outcome data. 
Furthermore, studies conducted on susceptible subpopulations (e.g. those with a family history of cancer, or 
ever-smokers) were not considered. SNPs associated with cancer at the standard threshold for genome-wide 
significance (p < 5 × 10−8) were selected.
A central assumption of Mendelian randomization is that instrumental variables are free of linkage disequi-
librium with one another (i.e. each genetic variant must be inherited independently of all others under consid-
eration). Analyses were, therefore, limited to genetic variants that were not in linkage disequilibrium (defined as 
r2 < 0.2) with other genetic variants for the same type of cancer in order to avoid a violation of this assumption. 
Pairwise linkage analysis of SNPs was undertaken using the National Cancer Institute LDMatrix tool (https://
analysistools.nci.nih.gov/LDlink/?tab=ldmatrix) based on the European subpopulation—Utah Residents from 
North and West Europe (CEU), Toscani in Italia (TSI), British in England and Scotland (GBI), and Iberian pop-
ulation in Spain (IBS)—reference panel of the 1000 Genomes Project. For genetic variants in linkage disequi-
librium, the variant with the lowest p-value for association with cancer was selected. Similarly, for each cancer 
susceptibility locus, the lead SNP, representing the variant with the lowest p-value of association, was selected.
Identifying proxy SNPs. When cancer-associated genetic variants were unavailable in the outcome dataset, prox-
ies in pairwise linkage disequilibrium (defined by r2 > 0.9) were used, where available. Identification of proxy 
SNPs was undertaken using the National Cancer Institute LDlink platform’s LDproxy tool (https://analysistools.
nci.nih.gov/LDlink/?tab=ldproxy) based on the European subpopulation—CEU, TSI, GBI, and IBS— reference 
panel of the 1000 Genomes Project. Proxy SNP effect alleles were assigned according to correlation information 
between alleles, provided on the LDpair tool provided through the National Cancer Institute LDlink platform.
Obtaining effects of cancer-associated SNPs on AD. Summary statistics describing the association 
between each cancer-related SNP and risk of AD were obtained from IGAP17,18. IGAP includes genotyped and 
imputed data on SNPs from 17,008 AD cases and 37,154 controls of European ancestry from four genome-wide 
association studies: (1) The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium 
(CHARGE), (2) The Alzheimer’s Disease Genetics Consortium (ADGC), (3) The Genetic and Environmental 
Risk in Alzheimer’s disease consortium (GERAD), and (4) The European Alzheimer’s disease Initiative (EADI). 
A summary of each dataset is provided in Supplementary Table 1. Diagnostic criteria for AD used in each study 
are provided in Supplementary Table 2.
Imputation and SNP selection. SNPs with call rates <95% were excluded from consideration in IGAP. The gen-
otypes of all individuals were imputed with haplotypes from samples of European ancestry in the 1000 Genome 
Project using IMPUTE219 or MaCH/Minimac20. SNPs with a minor allele frequency of <1% or with R2 (MaCH) 
or info score quality (IMPUTE2) estimates less than 0.3 were excluded from analyses. A total of 8,133,148 SNPs 
was retained for analysis.
In each dataset, the association between genotype dosage and AD was analyzed by logistic regression. The 
model was adjusted for age, sex, and principal components to account for possible population stratification. For 
the CHARGE cohorts containing incident AD cases, Cox proportional hazards regression models were used 
instead. The consortia used different, but comparable software for these analyses (PLINK (ACT, ADC, ADNI, 
AGES, GSK, MAYO, OHSU, ROSMAP, TGEN2, UMVUMSS, and UPITT), SNPTEST (GERAD), ProbABEL 
(AGES, CHS, EADI, FHS, and RS) or R (LOAD, MIRAGE)21–23. SNPs with logistic regression |β| > 5 or p-value 
equal to 0 or 1 were excluded. The maximum number of SNPs in any data set was 8,131,643. SNPs that were gen-
otyped/imputed in at least 40% of AD cases and 40% of controls were included in the meta-analysis. This led to a 
final number of 7,055,881 SNPs for analysis.
Statistical analysis. For the meta-analysis, fixed-effects inverse variance-weighted meta-analysis was applied, 
with the standard errors of the β-coefficient scaled by the square roots of study-specific genomic inflation factors 
(estimated before combining summary statistics across all datasets). METAL and GWAMA software packages 
were used for these analyses24,25.
Statistical analysis of two-sample Mendelian randomization. Calculating inverse-variance weighted 
ratio estimates and evaluating the role of chance. Two-sample Mendelian randomization is a statistical method 
that can be applied to summary statistics from GWAS to estimate the causal effect of an exposure (in this case, 
cancer) on an outcome (in this case, AD). “Two-sample” refers to the fact that summary association results for the 
exposure and the outcome are estimated in non-overlapping sets of individuals26.
An instrumental variable ratio estimate was calculated for each cancer-associated SNP as follows: First, the 
exposure and outcome files were harmonized on SNPid and effect allele. Then, the effect size estimate (β) for the 
association of the SNP with risk of AD was divided by the effect size estimate for the association of the same SNP 
with risk of cancer, producing a ratio of association estimates for each SNPj (θˆj) as follows27:
θ
β
β
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ˆ
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The ratio estimates from each SNP were then averaged using the inverse-variance weighted formula, adopted 
from the meta-analysis literature, to produce an overall causal estimate, the inverse-variance weighted (IVW) 
estimate. First-order weights were selected for the IVW method, as uncertainty in effect estimates was minimized 
through the use of large sample sets in identifying genetic instruments for cancer. The variance term was calcu-
lated as27:
β
β
ˆ
ˆ
se ( )
(2)
Yj
Xj
2
2
And the pooled fixed-effect inverse-variance weighted estimate (θˆIVW) was calculated as27:
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Ratio estimates for each genetic variant were summarized as forest plots. All analyses were conducted in R 
version 3.5.0 (R foundation) using the two sample Mendelian Randomization package28. The full R script used for 
two-sample MR is provided in Appendix 1.
To assess the role of chance in our findings, we additionally calculated the Bayesian false-discovery rate 
(BFDR) for each result, irrespective of statistical significance.
Under frequentist inference, p-values represent the probability of the data given the hypothesis. A Bayesian 
approach can be used, instead, to assess the probability of a hypothesis given the data. BFDR can be calculated 
to identify noteworthy associations and prevent overinterpretation of statistically significant findings that are 
unlikely to be true. This method involves specification of the prior probability that the null hypothesis is false and 
combines this information with the p-value and study power to derive a more informative posterior probability 
that the null hypothesis is true. A range of priors was selected on the basis of available observational evidence. All 
analyses were conducted in R version 3.5.0 (R foundation) using the gap package. The full R script used for BFDR 
calculations is provided in Appendix 1.
Sensitivity analyses. MR-Egger intercept test: Conventional Mendelian randomization analysis relies on the 
assumption that genetic variants used as instrumental variables do not have pleiotropic effects—meaning that 
the chosen variants do not influence the outcome (AD) through any pathways other than the exposure (cancer). 
This, therefore, implies that the only causal pathway from a cancer-associated genetic variant to AD is via cancer 
associated biological pathways. While this may be a reasonable assumption when the risk factor under study is a 
protein biomarker and SNPs are located in or near the coding region for that protein, it is more questionable for 
polygenic exposures, such as cancer27. We, therefore, used the MR-Egger intercept test to detect violations of this 
assumption, assessing whether cancer-associated genetic variants have pleiotropic effects on AD that differ on 
average from zero— known as directional pleiotropy27. If the intercept is not significantly different from 0, there is 
no evidence to reject the null hypothesis of no directional pleiotropy. MR-Egger intercepts were calculated, using 
first-order weights, via the two-sample Mendelian randomization package, using R script provided in Appendix 1.
Leave-one-out analysis: To assess the robustness of the Mendelian randomization effect estimates and iden-
tify any potential outliers, each SNP was sequentially removed from analysis, conducting Y analyses with Y-1 
datapoints27. If the precision and direction of association between cancer-predicting SNPs and AD remain 
largely unaltered, this implies that the data are not driven by any outliers. Leave-one-out analyses and corre-
sponding plots were generated using the two-sample Mendelian randomization package via R script provided in 
Appendix 1.
Funnel plots of inverse standard error: Finally, any heterogeneity of effect estimates was visualized using fun-
nel plots depicting the causal effect estimates for each SNP on the x-axis and the inverse standard error (a measure 
of instrumental strength) for the association on the y-axis. Asymmetry about the vertical line is indicative of het-
erogeneity; furthermore, a correlation between effect size and instrument strength (which would result in asym-
metry) is an indicator of possible directional pleiotropy29. The funnel plots were generated using the two-sample 
Mendelian randomization package via R script provided in Appendix 1.
Patient involvement: No patients were involved in the design, recruitment, or conduct of this study. No 
patients were asked to advise on the interpretation of results or the writing of manuscript. Following publication, 
these results will be available to the general public.
Results
Defining instrumental variables for cancer. Identifying cancer types of interest. Following a system-
atic review of titles, abstracts, and content for eligibility, eleven papers were retrieved from PubMed and Web of 
Science (Fig. 2)5–9,11,13,30–33. Searching their respective bibliographies did not lead to any additional studies for 
inclusion. The results of the systematic literature review are summarized in Table 1 and Supplementary Tables 3 
and 4.
With the exception of two papers, all studies report an inverse association between cancer and risk of subse-
quent AD, albeit not always statistically significant at standard thresholds. Nominally significant estimates for a 
protective effect of cancer on risk of subsequent AD range from 13% reduced risk (HR 0.87, 95% CI 0.84 to 0.90)6 
to 69% reduced risk (HR 0.31, 95% CI 0.12 to 0.86)5. The smallest nominally significant estimate for a protective 
effect of cancer at any individual site on risk of subsequent AD was seen in individuals with non-melanoma skin 
cancer (HR 0.95, 95% CI 0.92 to 0.98)30, while the largest estimate was for colorectal cancer (RR 0.43, 95% CI 
0.23 to 0.74)13. Only data supporting a protective role of cancer in AD reached statistical significance. However, 
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this inverse relationship is not uniformly observed across individual cancer types. For instance, while one study 
reports a 57% reduction in risk of AD in those with a history of colorectal cancer (RR 0.43, 95% CI 0.23 to 0.74)13, 
another found no nominally significant difference in the risk of AD in those with a history of colorectal cancer 
(RR 0.97, 95% CI 0.90 to 1.05)9. The same is true for non-melanoma skin cancer (HR 0.95, 95% CI 0.92 to 0.98 vs 
HR 0.18, 95% CI 0.024 to 1.34) (Table 1)7,30.
Furthermore, Driver and colleagues found a more robust inverse association between smoking-related cancers 
and AD, as compared to non-smoking related cancers and AD (Table 1). In light of these findings, together with 
the well-established negative association between smoking and Parkinson’s disease34, another neurodegenerative 
disorder, subsequent analyses were stratified by smoking versus non-smoking related cancers to further exam-
ine this association in the context of AD. Nominally significant effect estimates from observational studies for 
smoking-related cancers range from 9% reduced risk of AD (HR 0.91, 95% CI 0.86 to 0.96)6 to 40% reduced risk 
of AD (HR 0.6, 95% CI 0.34 to 0.98)13. For non-smoking related cancers, nominally significant effect estimates 
range from 5% reduced risk of AD (HR 0.95, 95% CI 0.92 to 0.98)30 to 57% reduced risk of AD (RR 0.43, 95% CI 
0.23 to 0.74) (Table 1)13.
Identifying cancer-associated genetic variants. GWAS data were available for 6 smoking-related cancers—renal 
cancer carcinoma, cervical cancer, pancreatic cancer, upper aerodigestive tract cancer, urinary bladder cancer, 
and lung cancer— in the GWAS Catalog repository. Six additional non-smoking related cancers— prostate can-
cer, leukemia, breast cancer, melanoma, lymphoma, and ovarian cancer— were selected on the basis of SNP 
information availability within the repository.
Per the inclusion criteria, 60 GWAS were deemed eligible for consideration (Supplementary Table 5). A total of 
314 genetic variants were identified as instrumental variables for cancer (Renal carcinoma: 25; pancreatic cancer: 
13; upper aerodigestive tract cancer: 14; urinary bladder cancer: 11; lung cancer: 18; cervical cancer: 1; prostate 
cancer: 36; leukemia: 38; breast cancer: 109; melanoma: 24; lymphoma: 20; ovarian cancer: 19) (Supplementary 
Tables 5 and 6). The lead SNP (based on the lowest reported p-value from GWAS) at each locus was selected. The 
lead SNP was also selected for any SNPs in linkage disequilibrium.
Identifying proxy SNPs. Of the 314 identified genetic variants, 26 were not available in IGAP. Seven SNPs had 
suitable proxies (defined as r2 > 0.9) within the European subpopulation reference panel of the 1000 Genomes 
Project, and nineteen SNPs did not have suitable proxies (Supplementary Table 7).
Obtaining effects of cancer-associated SNPs on Alzheimer’s disease. International genomics of 
alzheimer’s project. The International Genomics of Alzheimer’s Project datafile consists of the following infor-
mation for 7,055,881 SNPs and their associations with AD (based on meta-analysis, as described previously): 
Figure 2. Schematic overview of systematic literature search process and results.
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Cancer type Reference
Hazard ratio (95% 
confidence interval) Covariates
Smoking-related cancers
Smoking-related** Driver et al., 2012‡ 0.26 (0.08–0.82) Age, sex, and smoking
Lung Musicco et al., 2013 0.60 (0.34–0.98)♦ Age, sex, and calendar year of follow-up
Bladder Musicco et al., 2013 0.81 (0.48–1.27)♦ Age, sex, and calendar year of follow-up
Smoking-related* Freedman et al., 2016 0.91 (0.86–0.96) Race, sex, and number of doctors’ visits, birth year, and cancer registry area
Lung Frain et al., 2017 0.79 (0.71–0.89) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race
Bladder Frain et al., 2017 1.01 (0.92–1.11) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race
Head and neck Frain et al., 2017 0.91 (0.80–1.02) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race
Renal Frain et al., 2017 0.79 (0.65–0.97) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race
Esophagus Frain et al., 2017 0.74 (0.52–1.05) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Pancreas Frain et al., 2017 0.77 (0.51–1.14) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Stomach Frain et al., 2017 0.86 (0.62–1.20) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Non-smoking related cancers
Non-smoking related Driver et al., 2012‡ 0.82 (0.57–1.19) Age, sex, and smoking
Breast Musicco et al., 2013 0.70 (0.46–1.03)♦ Age, sex, and calendar year of follow-up
Prostate Musicco et al., 2013 0.94 (0.56–1.46)♦ Age, sex, and calendar year of follow-up
Colorectal Musicco et al., 2013 0.43 (0.23–0.74)♦ Age, sex, and calendar year of follow-up
Non-melanoma skin 
cancer Schmidt et al., 2017 0.95 (0.92–0.98)
Age, sex, calendar period of cancer diagnosis, alcohol-related diagnosis, hospital-diagnosed 
obesity, hypertension, ischemic heart disease, congenstive heart failure, peripheral artery 
disease, chronic pulmonary disease, diabetes, cancer, and multiple sclerosis
Non-smoking related Freedman et al., 2016 0.86 (0.83–0.89) Race, sex, and number of doctors’ visits, birth year, and cancer registry area
Prostate Chung et al., 2016 1.71 (0.90–3.25) Geographical location, monthly income, urbanization level, hypertension, diabetes, coronary heart disease, hyperlipidemia, and stroke
Non-melanoma skin 
cancer White et al., 2013 0.18 (0.024–1.34)
Sex, education, occupation, hypertension, diabetes, coronary heart disease, and ApoE4 
status
Prostate Frain et al., 2017 1.08 (1.04–1.11) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Colorectal Frain et al., 2017 0.97 (0.90–1.05) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Melanoma Frain et al., 2017 1.11 (0.99–1.23) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Lymphoma Frain et al., 2017 0.86 (0.73–0.99) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Leukemia Frain et al., 2017 0.81 (0.68–0.97) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Myeloma Frain et al., 2017 0.80 (0.60–1.07) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Liver Frain et al., 2017 0.76 (0.46–1.23) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race.
Any cancer
Any Driver et al., 2012‡ 0.67 (0.47–0.97) Age, sex, and smoking
Any Musicco et al., 2013 0.57 (0.49–0.67)♦ Age, sex, and calendar year of follow-up
Any Realmuto et al., 2012 0.60 (0.40–1.10)¶ Age, sex, education, and smoking
Any Bowles et al., 2017 0.95 (0.77–1.17) Age at study entry, cohort, sex, education, diabetes, hypertension, heart disease, stroke, smoking status, low self-rated health, regular exercise, and body mass index
Any Yarchoan et al., 2017 0.73 (0.56–0.94)¶ Age, sex, education, race, and ApoE4 status
Any Freedman et al., 2016 0.87 (0.84–0.90) Race, sex, and number of doctors’ visits, birth year, and cancer registry area
Any White et al., 2013 0.95 (0.47–1.93) Sex, education, occupation, hypertension, diabetes, coronary heart disease, and ApoE4 status
Any Frain et al., 2017 1.00 (0.97–1.03) Number of clinic visits in the year before baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, and race
Any Roe et al., 2010 0.31 (0.12–0.86) Sex, race, education, age, income, smoking, >130% overweight, kilocalories expended in physical activity, and Cardiovascular Health Study clinic effect
Table 1. Observational evidence for cancer and risk of subsequent Alzheimer’s disease, by cancer type. Separate 
effect estimates are provided for smoking-related cancers, non-smoking related cancers, and all cancers 
together. Unless otherwise noted, the maximally adjusted effect estimate is displayed. *Smoking- related 
cancers include oral cavity and pharynx, lip, pancreas, lung and bronchus, larynx, cervix, kidney and renal 
pelvis, bladder, esophagus, and stomach. **Smoking- related cancers include oral, pharynx, larynx, esophagus, 
stomach, pancreas, lung, cervix, bladder, and kidney. ‡Maximally adjusted model was not chosen here, due to 
insufficient statistical power. ♦Relative risk ¶Odds ratio.
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Chromosome (Chromosome of the SNP (Build 37, Assembly Hg19)), Position (position of the SNP (Build 37, 
Assembly Hg19), MarkerName (SNP rsID or chromosome:position if rsID not available), Effect allele (refer-
ence allele (coded allele), Non Effect_allele (non-reference allele (non-coded allele)), Beta-coefficient (overall 
estimated effect size for the effect allele), Standard error (overall standard error for effect size estimate), P-value 
(meta-analysis p-value using regression coefficients (beta and standard error)).
The IGAP summary statistics corresponding to each cancer-related SNP are detailed in Supplementary 
Table 6.
Cancer type
No. of 
SNPs
Odds 
ratio
Lower 
confidence 
limit
Upper 
confidence 
limit P-value BFDR50% BFDR10% BFDR1% BFDR0.1%
Smoking-related cancers
Renal cell carcinoma 12 0.97 0.89 1.05 0.434 68.22 95.08 99.53 99.95
Pancreatic cancer 13 0.97 0.91 1.04 0.429 71.63 95.79 99.60 99.96
Upper aerodigestive tract cancer 14 0.96 0.90 1.03 0.235 64.60 94.26 99.45 99.95
Urinary bladder cancer 11 0.94 0.83 1.06 0.325 58.76 92.77 99.30 99.93
Lung cancer 18 0.91 0.84 0.99 0.019 20.57 69.98 96.25 99.62
Smoking-related cancers (all) 68 0.95 0.92 0.98 0.003 7.11 40.78 88.33 98.71
Non-smoking related cancers
Prostate cancer 36 0.98 0.95 1.01 0.234 77.05 96.80 99.70 99.97
Leukemia 38 0.98 0.96 0.995 0.012 34.13 82.35 98.08 99.81
Breast cancer 109 0.94 0.89 0.99 0.028 30.32 79.66 97.73 99.77
Melanoma 24 0.98 0.93 1.03 0.447 76.52 96.70 99.69 99.97
Lymphoma 20 1.01 0.95 1.07 0.764 79.89 97.28 99.75 99.98
Ovarian cancer 19 1.01 0.96 1.06 0.797 81.76 97.58 99.78 99.98
Non-smoking-related cancers (all) 246 0.98 0.97 0.995 0.009 34.62 82.65 98.13 99.81
Smoking/non-smoking related cancers
All cancers 314 0.98 0.96 0.99 2.7E-4 2.19 16.74 68.86 95.71
Table 2. Results of conventional Mendelian randomization analysis for cancer and Alzheimer’s disease. 
Genetically predicted lung cancer, leukemia, breast cancer, smoking-related cancers, non-smoking related 
cancers, and all cancers taken together were associated with significantly lower odds of Alzheimer’s disease. The 
Bayes False Discovery Rate (BFDR) is also provided for each result as an approximation of the false positive rate. 
BFDR50% = Bayes False Discovery Rate at prior of 50%, BFDR10% = Bayes False Discovery Rate at prior of 10%, 
BFDR1% = Bayes False Discovery Rate at prior of 1%, BFDR0.1% = Bayes False Discovery Rate at prior of 0.1.
Figure 3. Odds ratio of Alzheimer’s disease per genetically predicted increase in risk of cancer. Each circle 
represents the inverse-variance weighted Mendelian randomization estimate for the causal effect of the 
corresponding genetically predicted cancer on Alzheimer’s disease. Dark blue represents smoking- related 
cancers, steel blue represents non-smoking related cancers, and orange represents all cancers in aggregate. 
Approximately 86% of points fell to the left of the null (OR = 1), while 14% fell to the right of the null. 
Genetically predicted lung cancer, leukemia, and breast cancer, as well as smoking-related cancers, non-
smoking related cancers, and all cancers together were associated with significantly lower odds of Alzheimer’s 
disease.
8Scientific RepoRtS |         (2019) 9:13548  | https://doi.org/10.1038/s41598-019-49795-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Two-sample mendelian randomization. Inverse-variance weighted effect estimates and false discovery 
rate. Genetically predicted smoking-related cancers were associated with 5.2% lower odds of AD (OR 0.95, 
95% CI 0.92 to 0.98, p = 0.0026; BFDR50% = 7.11%, BFDR10% = 40.78%, BFDR1% = 88.34%, BFDR0.1% = 98.71%) 
per 1-unit higher log odds of cancer (Table 2 and Fig. 3). Within smoking-related cancers, only genetically pre-
dicted lung cancer, with a 9.0% reduction, was associated with AD (OR 0.91, 95% CI 0.84 to 0.99, p = 0.019; 
BFDR50% = 20.57%, BFDR10% = 69.98%, BFDR1% = 96.25%, BFDR0.1% = 99.62%) per 1-unit higher log odds of 
cancer (Table 2 and Fig. 3). As only one susceptibility locus was identified for cervical cancer, separate Mendelian 
randomization analyses were not conducted for cervical cancer; however, its corresponding SNP was used in the 
pooled analysis of all smoking-related cancers.
Genetically predicted non-smoking related cancers were associated with 1.9% lower odds of AD (OR 0.98, 
95% CI 0.97 to 0.995, p = 0.0091; BFDR50% = 34.62%, BFDR10% = 82.65%, BFDR1% = 98.13%, BFDR0.1% = 99.81%) 
per 1-unit higher log odds of cancer (Table 2 and Fig. 3). Within non-smoking related cancers, genetically pre-
dicted prostate cancer, melanoma, lymphoma, and ovarian cancer were not associated with differential odds of 
developing AD. However, genetically predicted leukemia was associated with 2.4% reduced odds of AD (OR 0.98, 
95% CI 0.96 to 0.995, p = 0.012; BFDR50% = 34.13%, BFDR10% = 82.34%, BFDR1% = 98.09%, BFDR0.1% = 99.81%) 
per 1-unit higher log odds of cancer, and breast cancer was associated with 5.9% lower odds of AD (OR 0.94, 95% 
CI 0.89 to 0.99, p = 0.028; BFDR50% = 30.32%, BFDR10% = 79.66%, BFDR1% = 97.73%, BFDR0.1% = 99.77%) per 
1-unit higher log odds of cancer (Table 2 and Fig. 3).
When genetic predictors of cancers at all sites under consideration were pooled, cancer was associated with a 
2.5% reduction in odds of AD (OR 0.98, 95% CI 0.96 to 0.99, p = 0.00027; BFDR50% = 2.18%, BFDR10% = 16.74%, 
BFDR1% = 68.86%, BFDR0.1% = 95.71%) per 1-unit higher log odds of cancer (Table 2 and Fig. 3).
Sensitivity analyses. MR-Egger intercept test: Pleiotropy was assessed based on the intercept of MR-Egger anal-
ysis and Cochran’s Q. In all cases, there was no evidence to reject the null hypothesis of no unmeasured direc-
tional pleiotropy of the genetic variants in MR- Egger analyses (i.e. MR-Egger intercept of 0) (Table 3). There was 
evidence of heterogeneity from Cochran’s Q statistic for smoking-related, non-smoking related, and all cancers 
(Table 3).
Leave-one-out analysis: To further examine the stability of the Mendelian randomization effect estimates and 
identify any important outliers, each SNP was sequentially removed from the analysis, conducting Y analyses 
with Y-1 datapoints. The precision and direction of the association between cancer and risk of AD remained 
largely unaltered with this approach. Only four SNPs had a marginal influence on the overall estimate (namely, for 
the association between lung cancer and AD and breast cancer and AD). Plots of leave-one-out analysis showing 
the influence of individual SNPs on the overall effect estimate for each cancer type and risk of AD are provided 
in Appendix 2.
Funnel plots of inverse standard error: Any heterogeneity of effect estimates, and thereby the likelihood of 
directional pleiotropy of SNPs, was assessed on the basis of funnel plots depicting the inverse standard error of the 
causal estimate for each genetic variant. Asymmetry about the vertical line is indicative of heterogeneity, possibly 
due to pleiotropy. Figure 4 depicts the funnel plots for lung cancer, smoking-related cancers, leukemia, breast 
cancer, non-smoking related cancers, and all cancers.
Discussion
Our results are consistent with a protective effect of some cancer-related gene variants against Alzheimer’s disease, 
and support genetically mediated mechanisms for the inverse epidemiological association. Specifically, genes 
associated with increased risk of cancer at any site were associated with a reduced risk of Alzheimer’s disease, and 
across individual cancer types, lung cancer, breast cancer, and leukemia were found to be associated with a sta-
tistically significant lower risk of AD. Finally, genetically predicted smoking-related cancers were more strongly 
associated with AD than non-smoking related cancers. This Mendelian randomization approach provides critical 
information on causality, beyond the former epidemiological observations, with important implications for pub-
lic health and the prevention of both cancer and AD.
Taken together, the results of our Mendelian randomization complement and extend existing observational 
evidence of an inverse relationship between cancer and AD. Two studies synthesized observational data covering 
multiple cancer types to compare the relationship between smoking-related cancers and AD with the relation-
ship between non-smoking related cancers and AD6,11. In line with their findings, our study demonstrates an 
inverse causal relationship between genetically predicted cancers and risk of AD and, furthermore, supports a 
Cancer type Intercept
Standard 
error P-value Q Q P-value
Lung cancer 0.024 0.014 0.118 16.79 0.209
Leukemia −0.004 0.008 0.645 34.10 0.732
Breast cancer −0.001 0.004 0.770 111.22 0.153
Smoking-related cancers −0.003 0.008 0.695 84.73 0.006
Non-smoking related cancers −0.002 0.002 0.254 265.01 0.038
All cancers −0.003 0.002 0.167 353.53 0.002
Table 3. MR-Egger intercept test for unbalanced horizontal pleiotropy. In all cases, there is no evidence of 
unbalanced horizontal pleiotropy from the MR Egger Test. Cochran’s Q statistic is significant for smoking-
related, non-smoking related, and all cancers.
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stronger relationship between genetically predicted smoking-related cancers and AD than genetically predicted 
non-smoking related cancers and AD.
Strengths of this study include the use of data from large GWAS of cancer, as well as the MR design, which 
reduces confounding and bias from reverse-causality. Furthermore, the validity of MR relies on the assumptions 
that the instrumental variables are strongly associated with the risk factor of interest, are not associated with 
any confounders, and do not influence the outcome through alternative causal pathways (Fig. 5)35. These factors 
were addressed in the study design36. While relying on published summary statistics for our analyses means 
that instrumental variable strengths cannot be formally evaluated through the calculation of an F-statistic37, any 
instrumental bias would, in this case, be in the direction of the null, given that analyses were undertaken in sepa-
rate settings for the exposure and outcome38. Therefore, bias from weak instruments cannot explain the observed 
relationship between cancer and AD. Furthermore, while the wide range of risk factors for AD and the complex, 
Figure 4. Funnel plots depicting the relationship between the causal effect of cancer on Alzheimer’s disease 
estimated by each genetic variant against the inverse standard error of the causal estimate. The x-axis represents 
the effect estimate (beta-coefficient) for risk of Alzheimer’s disease for each SNP. The y-axis represents the 
standard error of the estimated effect. The blue vertical line represents the inverse-variance weighted Mendelian 
randomization estimate using all SNPs. In all cases, the estimated effects scatter roughly symmetrically about 
the overall Mendelian randomization estimate, indicating precision in the estimated effects as well as absence of 
pleiotropic effects. (a) lung cancer (b) smoking-related cancers (c) leukemia (d) breast cancer (e) non-smoking 
related cancers (f) all cancers.
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interlaced nature of physiological signaling complicate this assumption, results of the MR-egger intercept test, as 
discussed above, demonstrate that pleiotropy is unlikely to explain the observed association between cancer and 
AD. While there was evidence for heterogeneity of effect from Cochran’s Q statistics for some cancers, there was 
little to suggest that specific SNPs contributed to this heterogeneity based on leave-one-out analyses. Moreover, 
measurement error in the exposure can lead to heterogeneity when no pleiotropy is present39.
Nonetheless, our results must be considered in the context of several important limitations. An important 
potential limitation is the variability in the diagnostic criteria used to identify AD in IGAP studies and the inevi-
table possibility of misclassification bias. Another potential source of bias in Mendelian randomization analysis is 
population stratification. However, the IGAP dataset is restricted to individuals of European ancestry, thus reduc-
ing this possibility. Finally, cancer is a binary causal exposure that can be considered as a continuous variable 
representing cancer risk. It has been shown that a binary exposure that is a dichotomization of a continuous risk 
factor can lead to violation of the exclusion restriction assumption and limit the inferences drawn from an MR 
study40. However, this only affects the causal effect estimate and, provided the instrumental variable assumptions 
are satisfied, the use of MR to test the causal null hypothesis remains valid.
We present largely concordant results from Bayesian and frequentist statistical analyses, while recognizing the 
very different nature of the statistical tests. The Bayesian analysis quantifies the relative probability of alternative 
hypotheses (including a null hypothesis) given the observed data distributions. In view of the consistency of exist-
ing observational evidence for smoking-related cancers, a BFDR prior of 50% was used, while a more stringent 
prior of 10% was used to evaluate non-smoking related cancers. Under these assumptions, a caveat is necessary for 
the interpretation of the apparent associations for breast cancer, leukemia, and non-smoking related cancers (not-
ing the BFDR = 30% for breast cancer, 34% for leukemia, and 35% for non-smoking related cancers). However, 
when all cancers are considered in aggregate, or just smoking-associated cancers, the Mendelian randomization 
approach indicates that genes associated with cancer are associated with lower risk of AD. Twenty-eight genetic 
variants linked to cancer were associated with lower odds of AD, 13 of which are located either on or near genes 
that have been previously linked with AD (Supplementary Table 6). The remaining 15 SNPs merit further study, 
as they may contribute in developing novel diagnostic and prognostic tools for AD, as well as effective treatments 
strategies for the condition.
Expansion of this study and replication in other ethnic cohorts will be necessary to determine the external 
validity of our findings. Future studies should additionally seek to investigate the relationship between cancer 
and other forms of neurodegeneration, broadly. Ultimately, these results may provide grounds for cautious opti-
mism about the prospects for drug repurposing from cancer to AD—which may help to shorten the timelines for 
dementia drug discovery—and emphasize that genetic studies can help to deconvolute the complex interrelation 
between these two disorders.
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